SSC
ELVN icon

Spruce Street Capital’s Enliven Therapeutics ELVN Stock Holding History

Spruce Street Capital’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.7M Hold
329,006
– – 3.28% 10
2026
Q1 		$12.9M Sell
329,006
-117,078
-26% -$3.24M 3.1% 11
2025
Q4 		$6.87M Buy
+446,084
New +$8.89M 2.27% 15

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Spruce Street Capital's ELVN Position: Q2 2026 in Review

Spruce Street Capital held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 329,006 shares worth $16.7M. The position accounts for 3.28% of the portfolio, ranked #10.

Spruce Street Capital first reported a position in ELVN in Q4 2025 and has held it in 3 quarters since. 210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Spruce Street Capital held 329,006 shares of Enliven Therapeutics worth $16.7M as of Q2 2026.
  • Spruce Street Capital left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up 3.28% of Spruce Street Capital's portfolio in Q2 2026, its #10 holding.
  • Spruce Street Capital first reported a position in Enliven Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Spruce Street Capital's 13F filing for Q2 2026, filed 13 Aug 2026.